Stock Events

Stock Events

Pulmatrix 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2025
Next
-0.21
0.13
0.46
0.79
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-4.52MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2PU1.MU. It's not an investment recommendation.
AMD
7
AMD
Tesla
5
TSLA
NIO
5
NIO
Plug Power
5
PLUG

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals focuses on developing inhalation therapies for cystic fibrosis, directly competing with Pulmatrix's respiratory disease treatments.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline produces a range of respiratory products, including treatments for asthma and COPD, competing in the same market as Pulmatrix.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca has a strong portfolio in respiratory care, including treatments for asthma and COPD, making it a direct competitor to Pulmatrix.
Insmed
INSM
Mkt Cap24.19B
Insmed Incorporated specializes in rare lung diseases, offering products that compete with Pulmatrix's treatments for respiratory disorders.
Champion Industries
CHMP
Mkt Cap1,129
ChampionX Corporation, though not a direct pharmaceutical competitor, provides technologies and solutions that could indirectly compete with Pulmatrix's drug delivery technologies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries has a broad portfolio that includes respiratory treatments, competing with Pulmatrix in the generic and specialty medicine sectors.
Novartis
NVS
Mkt Cap305.1B
Novartis offers a wide range of healthcare products, including treatments for respiratory conditions, making it a competitor in the broader healthcare market.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. develops medications for various conditions, including respiratory diseases, positioning it as a competitor in the pharmaceutical industry.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a diverse portfolio of health care products, including treatments for respiratory conditions, competing across multiple segments with Pulmatrix.
Biogen
BIIB
Mkt Cap31.91B
Biogen focuses on advanced therapies for serious diseases, including respiratory conditions, indirectly competing with Pulmatrix in the biopharmaceutical sector.

About

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Show more...
CEO
Mr. Peter Ludlum CMA, MBA
Employees
2
Country
United States
ISIN
US74584P2020

Listings

MU
DE
2PU1.MU
F
DE
2PU.F
STU
DE
2PU.STU
XNAS
US
PULM

0 Comments

Share your thoughts

FAQ

What is Pulmatrix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Pulmatrix stocks are traded under the ticker 2PU1.MU.
When is the next Pulmatrix earnings date?▼
Pulmatrix is going to release the next earnings report on August 12, 2026.
What were Pulmatrix earnings last quarter?▼
2PU1.MU earnings for the last quarter are -0.21 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pulmatrix revenue for the last year?▼
Pulmatrix revenue for the last year amounts to 0 EUR.
What is Pulmatrix net income for the last year?▼
2PU1.MU net income for the last year is -4.52M EUR.
How many employees does Pulmatrix have?▼
As of July 13, 2026, the company has 2 employees.
In which sector is Pulmatrix located?▼
Pulmatrix operates in the Health & Wellness sector.
When did Pulmatrix complete a stock split?▼
Pulmatrix has not had any recent stock splits.
Where is Pulmatrix headquartered?▼
Pulmatrix is headquartered in Framingham, United States.